Stem cell IVF could enable same-sex couples and single parents to have genetically related children. It’s time to think ...

Researchers developed a topical gene therapy that corrects disease-causing mutations in human skin models using lipid ...

New scientific methods could one day render animal studies—the standard in research laboratories for more than 100 years—obsolete. Clive Svendsen, Ph.D., executive director of the Board of Governors ...

TORONTO, Oct. 13, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell-based cellular therapies, today announced a $62 million Series B financing ...

Neurodegenerative diseases like Parkinson's and Alzheimer's are characterized by irreversible neuron damage and limited natural repair mechanisms. While stem cell therapy holds great promise for ...

ElpasBio Holdings ("ElpasBio"), a leading clinical-stage biotechnology company focused on regenerative medicine, today announced that it has entered into a collaboration agreement with Fosun Kairos ...

A research team has identified the impact of stem cell infusion timing on the incidence and severity of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company's CRISPR-based ...

Researchers identified DMTF1 as a key transcription factor driving neural stem cell regeneration during aging. The study ...

Longeveron Inc., a biotechnology company focused on regenerative medicine, has licensed a US patent from the University of Miami aimed at developing cardiomyogenic precursor cells from pluripotent ...

MIAMI, July 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric ...